clascoterone
Dermatologicals (D10)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
pharma · Test of vasocontriction properties for classification of topical steroid potency
Cassopeia Pharmaceuticals Pvt
Cassiopea S.p.A.
Cassopeia Pharmaceuticals Pvt drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Chandigarh, IN HQ
2020 Founded
4 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Chandigarh, IN
- Founded
- 2020
- Employees
- 4
- Programs
- 1
- Drugs
- 6
- Patents
- 12
Cassopeia Pharmaceuticals Pvt pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cassopeia Pharmaceuticals Pvt drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Cassopeia Pharmaceuticals Pvt in public FDA and regional records.
-
Development asset linked to Cassopeia Pharmaceuticals Pvt in public FDA and regional records.
-
Development asset linked to Cassopeia Pharmaceuticals Pvt in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha.
- Target
- Adrenergic receptor alpha
- Mechanism
- Adrenergic receptor alpha agonist
-
Development asset linked to Cassopeia Pharmaceuticals Pvt in public FDA and regional records.